DNLI Quote, Financials, Valuation and Earnings

Armata Pharmaceuticals has a net margin of -- compared to Denali Therapeutics's net margin of --. Denali Therapeutics's return on equity of -- beat Armata Pharmaceuticals's return on equity of --.

Denali Therapeutics has a consensus price target of $36.63, signalling upside risk potential of 219.31%. On the other hand Armata Pharmaceuticals has an analysts' consensus of $7.00 which suggests that it could grow by 527.8%. Given that Armata Pharmaceuticals has higher upside potential than Denali Therapeutics, analysts believe Armata Pharmaceuticals is more attractive than Denali Therapeutics.

Denali Therapeutics has a beta of 1.581, which suggesting that the stock is 58.076% more volatile than S&P 500. In comparison Armata Pharmaceuticals has a beta of 0.914, suggesting its less volatile than the S&P 500 by 8.595%.

Denali Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Armata Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Denali Therapeutics pays -- of its earnings as a dividend. Armata Pharmaceuticals pays out -- of its earnings as a dividend.

Denali Therapeutics quarterly revenues are --, which are smaller than Armata Pharmaceuticals quarterly revenues of --. Denali Therapeutics's net income of -$114.8M is lower than Armata Pharmaceuticals's net income of $2.6M. Notably, Denali Therapeutics's price-to-earnings ratio is -- while Armata Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Denali Therapeutics is 5.53x versus 404.15x for Armata Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Perspective Therapeutics has a net margin of -- compared to Denali Therapeutics's net margin of --. Denali Therapeutics's return on equity of -- beat Perspective Therapeutics's return on equity of --.

Denali Therapeutics has a consensus price target of $36.63, signalling upside risk potential of 219.31%. On the other hand Perspective Therapeutics has an analysts' consensus of $14.39 which suggests that it could grow by 741.69%. Given that Perspective Therapeutics has higher upside potential than Denali Therapeutics, analysts believe Perspective Therapeutics is more attractive than Denali Therapeutics.

Denali Therapeutics has a beta of 1.581, which suggesting that the stock is 58.076% more volatile than S&P 500. In comparison Perspective Therapeutics has a beta of 1.199, suggesting its more volatile than the S&P 500 by 19.866%.

Denali Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Denali Therapeutics pays -- of its earnings as a dividend. Perspective Therapeutics pays out -- of its earnings as a dividend.

Denali Therapeutics quarterly revenues are --, which are smaller than Perspective Therapeutics quarterly revenues of --. Denali Therapeutics's net income of -$114.8M is lower than Perspective Therapeutics's net income of -$40.2M. Notably, Denali Therapeutics's price-to-earnings ratio is -- while Perspective Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Denali Therapeutics is 5.53x versus 11.07x for Perspective Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Electromed has a net margin of -- compared to Denali Therapeutics's net margin of 12.11%. Denali Therapeutics's return on equity of -- beat Electromed's return on equity of 15.91%.

Denali Therapeutics has a consensus price target of $36.63, signalling upside risk potential of 219.31%. On the other hand Electromed has an analysts' consensus of $37.00 which suggests that it could grow by 67.35%. Given that Denali Therapeutics has higher upside potential than Electromed, analysts believe Denali Therapeutics is more attractive than Electromed.

Denali Therapeutics has a beta of 1.581, which suggesting that the stock is 58.076% more volatile than S&P 500. In comparison Electromed has a beta of 0.594, suggesting its less volatile than the S&P 500 by 40.575%.

Denali Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Electromed offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Denali Therapeutics pays -- of its earnings as a dividend. Electromed pays out -- of its earnings as a dividend.

Denali Therapeutics quarterly revenues are --, which are smaller than Electromed quarterly revenues of $16.3M. Denali Therapeutics's net income of -$114.8M is lower than Electromed's net income of $2M. Notably, Denali Therapeutics's price-to-earnings ratio is -- while Electromed's PE ratio is 29.48x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Denali Therapeutics is 5.53x versus 3.32x for Electromed. Usually stocks with elevated PS ratios are considered overvalued.

Protalix BioTherapeutics has a net margin of -- compared to Denali Therapeutics's net margin of 35.65%. Denali Therapeutics's return on equity of -- beat Protalix BioTherapeutics's return on equity of 8.75%.

Denali Therapeutics has a consensus price target of $36.63, signalling upside risk potential of 219.31%. On the other hand Protalix BioTherapeutics has an analysts' consensus of $14.50 which suggests that it could grow by 535.97%. Given that Protalix BioTherapeutics has higher upside potential than Denali Therapeutics, analysts believe Protalix BioTherapeutics is more attractive than Denali Therapeutics.

Denali Therapeutics has a beta of 1.581, which suggesting that the stock is 58.076% more volatile than S&P 500. In comparison Protalix BioTherapeutics has a beta of 0.456, suggesting its less volatile than the S&P 500 by 54.351%.

Denali Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Protalix BioTherapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Denali Therapeutics pays -- of its earnings as a dividend. Protalix BioTherapeutics pays out -- of its earnings as a dividend.

Denali Therapeutics quarterly revenues are --, which are smaller than Protalix BioTherapeutics quarterly revenues of $18.2M. Denali Therapeutics's net income of -$114.8M is lower than Protalix BioTherapeutics's net income of $6.5M. Notably, Denali Therapeutics's price-to-earnings ratio is -- while Protalix BioTherapeutics's PE ratio is 76.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Denali Therapeutics is 5.53x versus 3.54x for Protalix BioTherapeutics. Usually stocks with elevated PS ratios are considered overvalued.